Oncotarget is one of the most reliable medical news journals which is peer reviewed. It covers all research related to oncology. The journal was set up seven years ago and is published by Impact Journals. Its editor in chief is Mikhail Blagosklonny. The mission of the journal is to make scientific results widely available and as fast as possible. The journal allows exceptional discoveries to be shared quickly, maximize the impact of research through insightful review. The journal also aims to eliminate borders between specialists. They seek to link different fields of biomedical science and to foster the application of basic and clinical science to realize the dream of a disease-free world.
The journal helps all researchers contribute in the progressing of science with the help of competent scientists. Some of the issues that are tackled by the journal are pathways, molecules, and cellular functions. They also tackle neurodegeneration, cancer, and atherosclerosis are another concern of the publication.One of the lead scientists and contributors to the magazine is Mikhail Blagosklonny. Mikhail is one of the best Oncology Professors at the Roswell Park Cancer Institute, based in New York. Mikhail has an Masters in cardiology and internal medicine from the First Pavlov State Medical University, which is located in Russia, where he also earned his Ph.D. in experimental medicine. Mikhail was appointed to the position of associate professor of medicine at New York Medical College in Valhalla in 2002. The job was right before he started working at the Ordway Institute of Research.
Blagosklonny held the position until 2009. He was then appointed an Oncology professor at Roswell Park Cancer Institute. Blagosklonny research interest is cancer and therapies that protect healthy cells from damage as well the underlying mechanisms of biogerontology, and anti-aging drugs. He has come up with a hypothesis on the role played by TOR signaling in aging and cancer, and proposed using rapamycin as a therapy.Rapamycin is a popular cancer drug which he thinks can be a possible treatment for life extension. Blagosklonny is also the editor-in-chief of Aging and Cell Cycle. He is an associate editor of Cancer Biology and Therapy. He is also a member of the editorial board of Cell Death and Differentiation. Blagosklonny is considered one of the most passionate advocates of rapamycin in longevity research.